checkAd
    Teva Pharmaceutical Industries Aktie
    16,000
     
    USD
    +1,65 %
    +0,260 USD
    Letzter Kurs 02:04:00 NYSE
    16,000
     
    USD
    70.800 STK
    Geldkurs 09.05.24
    16,010
     
    USD
    68.800 STK
    Briefkurs 09.05.24
    ISIN: US8816242098 · WKN: 883035 · SYM: TEVA · Israel

    Neueste Nachrichten

    Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
    08.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
    08.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva to Present at the 2024 Bank of America Healthcare Conference
    03.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
    02.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)
    30.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
    16.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO (deutetrabenazine) Tablets
    16.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
    11.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
    09.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY (risperidone) Extended-Release Injectable Suspension at SIRS 2024
    06.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
    04.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
    01.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries